Normalization of prandial blood glucose and improvement of glucose tolerance by liver-specific inhibition of SH2 domain-containing inositol phosphatase 2 (SHIP2) in diabetic KKAy mice: SHIP2 inhibition causes insulin-mimetic effects on glycogen metabolism, gluconeogenesis, and glycolysis

Diabetes

Volumn 56, Issue 9, 2007, Pages 2235-2241

  Grempler, Rolf ^a   Zibrova, Darya ^a   Schoelch, Corinna ^a   Van Marle, André ^b   Rippmann, Joerg F ^a   Redemann, Norbert ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b BioFocus DPI   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOKINASE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLYCOGEN PHOSPHORYLASE; GLYCOGEN SYNTHASE; PHOSPHATASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROTEIN KINASE B; PROTEIN SH2; PROTEIN SHIP2; PYRUVATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCOGEN LIVER LEVEL; GLYCOGEN METABOLISM; HYPERGLYCEMIA; HYPERINSULINEMIA; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADENOVIRIDAE; ANIMALS; BLOOD GLUCOSE; DNA; EATING; ENZYME INHIBITORS; GLUCONEOGENESIS; GLUCOSE; GLUCOSE TOLERANCE TEST; GLYCOGEN; GLYCOLYSIS; INSULIN; LIVER; MALE; MICE; PHOSPHORIC MONOESTER HYDROLASES; REFERENCE VALUES;

EID: 34548399078     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-1660     Document Type: Article

References (24)

1. Shepherd PR, Withers DJ, Siddle K: Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J 333:471-490, 1998
2. Ishihara H, Sasaoka T, Hori H, Wada T, Hirai H, Haruta T, Langlois WJ, Kobayashi M: Molecular cloning of rat SH2-containing inositol phosphatase 2 (SHIP2) and its role in the regulation of insulin signaling. Biochem Biophys Res Commun 260:265-272, 1999
3. Pesesse X, Deleu S, De Smedt F, Drayer L, Erneux C: Identification of a second SH2-domain-containing protein closely related to the phosphatidylinositol polyphosphate 5-phosphatase SHIP. Biochem Biophys Res Commun 239:697-700, 1997
4. Marion E, Kaisaki PJ, Pouillon V, Gueydan C, Levy JC, Bodson A, Krzentowski G, Daubresse JC, Mockel J, Behrends J, Servais G, Szpirer C, Kruys V, Gauguier D, Schurmans S: The gene INPPL1, encoding the lipid phosphatase SHIP2, is a candidate for type 2 diabetes in rat and man. Diabetes 51:2012-2017, 2002
5. Sleeman MW, Wortley KE, Lai KM, Gowen LC, Kintner J, Kline WO, Garcia K, Stitt TN, Yancopoulos GD, Wiegand SJ, Glass DJ: Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity. Nat Med 11:199-205, 2005
6. Sasaoka T, Hori H, Wada T, Ishiki M, Haruta T, Ishihara H, Kobayashi M: SH2-containing inositol phosphatase 2 negatively regulates insulin-induced glycogen synthesis in L6 myotubes. Diabetologia 44:1258-1267, 2001
7. Wada T, Sasaoka T, Funaki M, Hori H, Murakami S, Ishiki M, Haruta T, Asano T, Ogawa W, Ishihara H, Kobayashi M: Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulininduced metabolic actions in 3T3-L1 adipocytes via its 5′-phosphatase catalytic activity. Mol Cell Biol 21:1633-1646, 2001
8. Fukui K, Wada T, Kagawa S, Nagira K, Ikubo M, Ishihara H, Kobayashi M, Sasaoka T: Impact of the liver-specific expression of SHIP2 (SH2-containing inositol 5′-phosphatase 2) on insulin signaling and glucose metabolism in mice. Diabetes 54:1958-1967, 2005
9. Kwon HS, Huang B, Unterman TG, Harris RA: Protein kinase B-α inhibits human pyruvate dehydrogenase kinase-4 gene induction by dexamethasone through inactivation of FOXO transcription factors. Diabetes 53:899-910, 2004
10. Huang B, Wu P, Bowker-Kinley MM, Harris RA: Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-α ligands, glucocorticoids, and insulin. Diabetes 51:276-283, 2002
11. Bollen M, Keppens S, Stalmans W: Specific features of glycogen metabolism in the liver. Biochem J 336:19-31, 1998
12. Aiston S, Hampson LJ, Arden C, Iynedjian PB, Agius L: The role of protein kinase B/Akt in insulin-induced inactivation of phosphorylase in rat hepatocytes. Diabetologia 49:174-182, 2006
13. Velho G, Petersen KF, Perseghin G, Hwang JH, Rothman DL, Pueyo ME, Cline GW, Froguel P, Shulman GI: Impaired hepatic glycogen synthesis in glucokinase-deficient (MODY-2) subjects. J Clin Invest 98:1755-1761, 1996
14. Sugden MC, Holness MJ: Therapeutic potential of the mammalian pyruvate dehydrogenase kinases in the prevention of hyperglycaemia. Curr Drug Targets Immune Endocr Metabol Disord 2:151-165, 2002
15. Grempler R, Kienitz A, Werner T, Meyer M, Barthel A, Ailett F, Sutherland C, Walther R, Schmoll D: Tumour necrosis factor alpha decreases glucose-6-phosphatase gene expression by activation of nuclear factor kappaB. Biochem J 382:471-479, 2004
16. Bergmeyer HU: Methoden der Enzymatischen Analyse. Weinheim, Germany, Verlag Chemie, 1974 (in German)
17. Jaffe HA, Danel C, Longenecker G, Metzger M, Setoguchi Y, Rosenfeld MA, Gant TW, Thorgeirsson SS, Stratford-Perricaudet LD, Perricaudet M, et al.: Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet 1:372-378, 1992
18. Iwatsuka H, Shino A, Suzuoki Z: General survey of diabetic features of yellow KK mice. Endocrinol Jpn 17:23-35, 1970
19. Dong X, Park S, Lin X, Copps K, Yi X, White MF: Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. J Clin Invest 116:101-114, 2006
20. Schmoll D, Walker KS, Alessi DR, Grempler R, Burchell A, Guo S, Walther R, Unterman TG: Regulation of glucose-6-phosphatase gene expression by protein kinase Balpha and the forkhead transcription factor FKHR: evidence for insulin response unit-dependent and -independent effects of insulin on promoter activity. J Biol Chem 275:36324-36333, 2000
21. Zhang X, Gan L, Pan H, Guo S, He X, Olson ST, Mesecar A, Adam S, Unterman TG: Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms: direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding. J Biol Chem 277:45276-45284, 2002
22. Guo S, Dunn SL, White MF: The reciprocal stability of FOXO1 and IRS2 creates a regulatory circuit that controls insulin signaling. Mol Endocrinol 20:3389-3399, 2006
23. Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim YJ, Sherwin R, Devaskar S, Lesche R, Magnuson MA, Wu H: Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A 101:2082-2087, 2004
24. Ono H, Shimano H, Katagiri H, Yahagi N, Sakoda H, Onishi Y, Anai M, Ogihara T, Fujishiro M, Viana AY, Fukushima Y, Abe M, Shojima N, Kikuchi M, Yamada N, Oka Y, Asano T: Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement. Diabetes 52:2905-2913, 2003